16 results
8-K
EX-99.1
CERE
Cerevel Therapeutics Holdings Inc
1 Aug 22
Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
6:27am
of darigabat in acute anxiety.
oIn a separate panel presentation, Cerevel discussed efforts to achieve diversity in clinical trials, an imperative … that is a key component of a broader commitment to diversity, equity, and inclusion across all facets of the company.
Tavapadon: a D1/D5 partial agonist
8-K
EX-99.1
CERE
Cerevel Therapeutics Holdings Inc
15 Jun 22
Cerevel Therapeutics Announces Updates to its Board of Directors
6:30am
with a strong track record in building businesses, driving commercial success, and supporting diversity, equity, and inclusion,” Tony Coles, M.D
424B4
l4u055v6izfinc3txi
2 Jul 21
Prospectus supplement with pricing info
5:22pm
DRS
d7iw1b6
27 May 21
Draft registration statement
12:00am
DEF 14A
k50uxrte81gkbrfqs
28 Apr 21
Definitive proxy
4:13pm
424B3
lp4n2in6m2d u98x0
26 Mar 21
Prospectus supplement
4:31pm
POS AM
tnc56spvtoq hn0k
24 Mar 21
Prospectus update (post-effective amendment)
5:13pm
10-K
stds76m7lf96gfvx
24 Mar 21
Annual report
4:20pm
424B3
41dli381o jeciu4q1l
4 Dec 20
Prospectus supplement
4:58pm
- Prev
- 1
- Next